Trial Profile
Detection of Striatal Dopaminergic Degeneration and Neocortical Amyloid Pathology in Patients With Dementia With Lewy Bodies, Alzheimer's Disease, Parkinson's Disease, and Healthy Elderly Volunteers
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Florbenazine F18 (Primary) ; Florbetapir F 18 (Primary)
- Indications Alzheimer's disease; Lewy body disease; Parkinson's disease
- Focus Diagnostic use
- Sponsors Avid Radiopharmaceuticals
- 13 May 2014 New trial record